Text messages may aid medication adherence for teen diabetics
COLUMBUS, Ohio A pilot study conducted by an endocrinologist at Nationwide Children’s Hospital is looking to increase medication adherence among adolescent diabetic patients with text message alerts.
Doctor Jennifer Dyer found that a simple reminder, in the form of a text message, can be sent to her teenage patients to improve their medication adherence. During the study, she sent personalized questions and reminders specific to diabetes adherence activities, in addition to friendly, supportive messages to her patients. Dyer also applied for an internal grant in order to test an iPhone application that she has developed. This application will allow endocrinologists to send personalized, yet automated texts to multiple patients at a specific time.
“If adolescent diabetes patients do not adhere to their treatment and medication plans, it can result in difficulty concentrating in school or functioning throughout the day,” said Dyer, who also is an assistant professor of pediatrics at The Ohio State University College of Medicine. “Excellent control and treatment can have a long-term, positive effect on a patient with diabetes. This form of communication allows for real-time health management, which is extremely valuable for patients that suffer from a chronic illness like diabetes.”
Curemark gets nod to start late-stage trial for ADHD drug
RYE, N.Y. The Food and Drug Administration has approved a late-stage clinical trial of a drug for attention deficit hyperactivity disorder.
Curemark said the FDA cleared its application to run a phase 3 trial of CM-4612 in patients with ADHD. The company is currently conducting a phase 3 trial of CM-AT, a treatment for autism in children.
“We are very excited to have received [clearance] from the FDA so that we can move forward with clinical trials to study CM-4612,” Curemark CEO Joan Fallon said. “Curemark hopes to have the first physiologically based medication to address ADHD, in lieu of the current psychotropic and stimulant treatments.”
FDA approves additional dosage for NovoSeven RT
PRINCETON, N.J. The Food and Drug Administration has approved a new dose of a treatment for hemophilia from Novo Nordisk, the Danish drug maker said.
The FDA approved Novo Nordisk’s NovoSeven RT (coagulation factor VIIa [recombinant], room temperature stable) in 8-mg vials. The treatment, which comes in the form of a powder mixed for injection, was already available in 1, 2 and 5 mg vials. The FDA also approved an extension of shelf life for all vial sizes from 24 months to 36 months at or below 77 degrees.
NovoSeven RT is formulated for patients with hemophilia A or B with inhibitors. The new dosage will shorten the time it takes to prepare the injection, known as reconstitution, compared with current dosages.